论文部分内容阅读
运用免疫组化ABC技术对87例福尔马林固定石蜡包埋的乳腺癌组织进行回顾性研究。nm23为单克隆抗体（NM301）、P53为单克隆抗体D0－7，平均随访期67.84月。观察乳腺癌中P53和nm23基因蛋白表达，探讨其与临床病理参数、预后及PCNA、ER、PR的关系以及它们在预后判断上的相互关系。结果：P53阳性36例（41．38％），其蛋白表达显示，与病理分级Ⅲ级、核分裂、淋巴结转移、生存期短、复发脏器转移、PCNA阳性表达、ER阴性表达等预后不良的临床病理参数呈正相关趋势（P＜0．05）；nm23阳性45例（51．72％）与上述预后不良参数呈负相关趋势（P＜0．05）；在阻抑淋巴结转移和生存期等方面，它的作用更为显著（P＜0．001），同时，这两种蛋白表达之间可能存在着互相“拮抗”的负相关关系．
Using immunohistochemical ABC technique, 87 cases of formalin-fixed paraffin-embedded breast cancer tissues were retrospectively studied. Nm23 is a monoclonal antibody (NM301), P53 is a monoclonal antibody D0-7, and the average follow-up period is 67.84 months. The expressions of P53 and nm23 genes in breast cancer were observed and their relationship with clinicopathological parameters, prognosis, PCNA, ER, PR and their relationship in prognosis were explored. Results: P53 positive in 36 cases (41.38%), its protein expression, and pathological grade III, nuclear fission, lymph node metastasis, short survival time, recurrent organ metastasis, PCNA positive expression, ER negative expression and other poor prognosis of clinical Pathological parameters showed a positive correlation trend (P<0.05); nm23-positive 45 patients (51.72%) showed a negative correlation with the above-mentioned poor-prognosis parameters (P<0.05); they inhibited lymph node metastasis and survival, etc. , Its role is more significant (P <0.001), at the same time, there may be a negative correlation between the expression of these two proteins “antagonism”.